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Global situation of Hansen’s disease after multi-
drug therapy (MDT) - In 1982, the WHO Study Group 
on the Chemotherapy of Hansen’s Disease for Control 
Programme (WHO 1982) recognized an urgent need 
of new therapeutic approaches to face the problem of 
dapsone resistance detected in more than 40 endemic 
countries (WHO 1982, 1985). This study group strongly 
recommended the introduction of a new therapeutic 
regimen with association of drugs (dapsone, rifampi-
cin and clofazimine) known as MDT. Multibacillary 
(MB) patients should be treated with all three drugs 
until the skin smears became negative and paucibacil-
lary (PB) patients would receive dapsone and rifampicin 
for six months.
MDT was implemented in all endemic countries 
through the 80’s and has always been available free of 
charge. WHO and non-governmental organizations 
(NGOs) played a major role in this process. 
MDT promoted a shift in deep-seated paradigms 
among patients, health workers and population, such as 
leprosy being an incurable disease. Moreover, it was fea-
sible in the field, showed efficacy rates greater than 99% 
in MB and PB patients, with few side effects and turned 
drug resistance into a minor problem (WHO 1991). 
Leprosy treatment, formerly a lifetime therapy in 
most Hansen’s disease control programmes, was then 
possible to be discontinued. Later on, MDT duration for 
MB patients was successively reduced to two and one 
year and since 1982 MDT for PB patients has been ad-
ministered for six months.
At the completion of MDT, programme managers 
were instructed to release patients from regular control 
and remove them from the official records. This policy 
resulted in a tremendous reduction in the global preva-
lence from more than five million registered patients in 
the 80’s to less than one million at the end of the 90’s 
(WHO 1985, 1991). 
Success of MDT implementation and WHO goal of 
Hansen’s disease elimination by the year 2000 - Following 
the success of MDT, but without strong or incontestable 
evidence, leprosy elimination was the next step proposed 
by the WHO and Health Ministries of endemic countries 
during the 44th World Health Assembly held in May 1991 
(WHO 1991). This goal was defined as the reduction in 
prevalence to less than one patient per 10,000 inhabitants 
by the year 2000. It was assumed that such prevalence 
figures would so drastically impact the transmission of 
Mycobacterium leprae that, with time, leprosy would vir-
tually be extinct and any resurgence unlike (WHO 1991).
The implementation of Hansen’s disease elimina-
tion through MDT in all endemic countries, reaching 
patients even in very remote areas, is a hallmark in the 
leprosy control history (WHO 2003). WHO, NGOs and 
governments did a remarkable job together. Since 1985, 
more than 15 million patients have been cured through 
MDT (WHO 2010b).
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The introduction, implementation, successes and failures of multidrug therapy (MDT) in all Hansen’s disease 
endemic countries are discussed in this paper. The high efficacy of leprosy treatment with MDT and the global reduc-
tion of prevalence led the World Health Organization, in 1991, to establish the goal of elimination of Hansen’s disease 
(less than 1 patient per 10,000 inhabitants) to be accomplished by the year 2000. Brazil, Nepal and East Timor are 
among the few countries that didn’t reach the elimination goal by the year 2000 or even 2005. The implications of 
these aspects are highlighted in this paper. Current data from endemic and previously endemic countries that carry a 
regular leprosy control programme show that the important fall in prevalence was not followed by the reduction of the 
incidence. This means that transmission of Mycobacterium leprae is still an issue. It is reasonable to conclude that we 
are still far from the most important goal of Hansen’s disease control: the interruption of transmission and reduction 
of incidence. It is necessary to emphasize to health managers the need of keeping Hansen’s disease control activities 
to better develop control programmes in the future. The recent international proposal to interrupt the transmission 
of leprosy by the year 2020 seems to unrealistic and it is discussed in this paper. The possibility of epidemiological 
impact related to the human immunodeficiency virus/Hansen’s disease coinfection is also considered. 
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Impact of MDT in Hansen’s disease prevalence and 
incidence: current status with special reference to Índia, 
Brazil and Indonesia - The global number of new cases 
of leprosy has steadily declined from the peak of more 
than 775,000 in 2001 to 245,000 in 2009 (WHO 2010a).
In 2004, India launched the Hansen’s disease elimi-
nation monitoring with new standards for case definition 
in this country. These changes triggered a sudden drop 
of 63.6% in new reported cases from 367,143 in 2003 
to 133,717 in 2009. During the same time frame, global 
detection of new cases went down from 514,718 in 2003 
to 244,796 in 2009 (WHO 2010a). In short, India is the 
leading responsible country for the world prevalence of 
leprosy (Figs 1, 2).
Comparing the new leprosy cases detection trend 
among the three endemic countries - India, Indonesia 
and Brazil - it is observed that the last two countries pre-
sented a similar behaviour: a slow reduction of the inci-
dence from 2002-2008. This trend is more compatible 
with the epidemiological behaviour of Hansen’s disease, 
due to its long incubation period. 
In Brazil, another major endemic country, Hansen’s 
disease prevalence steadfastly declined and detection 
rates showed an increasing tendency in the last two dec-
ades of the 20th century, probably reflecting better pa-
tient access to primary health care (Penna et al. 2008). 
From 2007-2010, important changes were introduced 
in Brazil regarding Hansen’s disease public health poli-
cy. Disease control in patients less than 15 years of age 
and surveillance of contacts were defined as the most 
important strategies to reach the planned objectives. Ep-
idemiological studies were able to spot clusters of cases 
and greater risk of disease, therefore providing scientific 
basis for political and administrative actions (Penna et al. 
2008, 2011). During this period, the Brazilian Ministry 
of Health never hesitated in employing all governmental 
and diplomatic means available to include Hansen’s dis-
ease control - in Brazil and around the world - into the 
framework of evidence-based medicine.
Hansen’s disease control is based on early diagno-
sis and treatment, which allows the prompt elimination 
of transmission sources and the decrease of the hidden 
prevalence of infectious cases. However, the impact of 
Hansen’s disease control strategies can not be compared 
to that of other vaccine preventable infectious diseases. 
The reason is that in high risk areas, a significant propor-
tion of the adult population is already infected and may 
develop the condition (Penna 1988). In order to reduce the 
hidden prevalence, one must foster case detection which, 
in turn, implies in the increase of the known prevalence. 
In 2007, 10 clusters with a strong concentration of 
new cases were identified in Brazil. These areas, which 
comprised 173 of the nearly 5,000 Brazilian munici-
palities and 10% of the country population, accounted 
for 53.5% of the new cases reported (Penna et al. 2008, 
2009). These areas were given top priority as to epide-
miological surveillance, treatment, prevention of inca-
pacities and rehabilitation (Penna et al. 2009, 2011).
The majority of endemic countries that reached the 
elimination goal did so by following World Health Organ-
ization guidelines (WHO 2003). However, statistical data 
from WHO must be interpreted with caution. According 
to Fine (2006), India’s criteria for prevalence and detec-
tion are doubtful and questionable and, hence, it is quite 
likely that this country and maybe the whole world, has 
not reached yet prevalence rates established by the WHO 
for the elimination goal. Actions proposed by the India 
programme (Leprosy Elimination Monitoring) included 
recommendations that new cases could only be reported 
after diagnostic confirmation by a leprologist, patients 
with single lesion or relapsed patients should be excluded 
from prevalence and withdrawal of dropout patients from 
active records (Britton & Lockwood 2004, Samy 2007).
Another intriguing aspect of Hansen’s disease epide-
miology is that, in spite of the efficacy of MDT and its 
wide use for over 25 years, the impact on the transmission 
of M. leprae is not as strong as expected (Britton & Lock-
wood 2004, Rothman et al. 2008, Rodrigues & Lockwood 
2011). Although prevalence has dropped during the last 
two decades, incidence has fallen quite slowly (Penna et 
al. 2011). Also, prevalence decrease after the introduction 
of MDT was not paralleled by the decrease of new cases, 
indicating that prevalence is not a suitable parameter to 
measure disease control (Britton & Lockwood 2004). Ac-
cording to the WHO, new cases of leprosy, although not 
many, are still diagnosed in countries that have reached 
the elimination goal, stressing the need for permanent ac-
tions from governments (Penna et al. 2011).
The number of countries with reported new cases 
has risen from 121 in 2008 to 141 in 2009. In 2008, six 
countries - China, Madagascar, Nepal, Nigeria, Sudan 
and Tanzania - showed an increase in new cases as com-
pared to 2007. In 2009, Ethiopia, Philippines and Sudan 
detected more cases than in 2008 (WHO 2009, 2010a).
Fig. 1: global leprosy new case detection (NCD) between 1985-2010. 
Source: WHO (2012).
Fig. 2: global leprosy new case detection (NCD) trend excluding the 
data of India. Source: WHO (2012).
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Hansen’s disease elimination and human immunode-
ficiency virus (HIV)/leprosy coinfection - Brazil is one 
of the countries where Hansen’s disease and acquired 
immune deficiency syndrome (AIDS) are endemic. 
From 1980-2007, 506,499 cases of HIV infection were 
reported, with a detection rate of 17.8 cases per 100,000 
inhabitants (MS/SVS 2008, WHO 2009, 2010a).
Worldwide data indicate that, contrary to early expec-
tations, no signiﬁcant increase in Hansen’s disease and 
HIV coinfection has been reported (Ustianowski et al. 
2006). Most of the large studies on the subject were per-
formed in the early to mid-1990s, examining the rate of 
HIV seropositivity among leprosy patients in India (Se-
kar et al. 1994), Brazil (Andrade et al. 1997, Machado et 
al. 1998) and African countries (Poennighaus et al. 1991, 
Lienhardt et al. 1996). In Brazil, studies suggest that, in 
coinfected patients, each disease progresses as a separate 
infection (Sampaio et al. 1995, Pereira et al. 2004).
However, one study probably addressed the true es-
timate of the prevalence of leprosy and HIV infection 
in populations exposed to both diseases, in a cohort re-
cruited in Manaus, a city located in the Brazilian Ama-
zon Region, where both leprosy and AIDS are endemic. 
Considering that the institution where the study was con-
ducted (Institute of Tropical Medicine) is a referral centre 
for both diseases, it is possible that the 25 cases of leprosy 
and HIV coinfection out of a total of 3,290 HIV-positive 
individuals reported between 1996-June 2009 (SINAN 
2009) represent the closest estimate of the prevalence of 
this coinfection in a major Brazilian city. Since the preva-
lence of leprosy in the state of Amazonas was 2.92/10,000 
in 2008, these data clearly indicates a higher Hansen’s 
disease prevalence among HIV-positive individuals when 
compared to the general population (Talhari 2010).
Further studies are needed to better evaluate HIV/
leprosy coinfection and its impact on elimination goals. 
The emphasis on the reduction of grade 2 of physical 
deformity among new cases, as recommended by the last 
WHO Expert Panel, is a challenge for Hansen’s disease 
control programmes and obligate that detection should 
be prioritized (Bobin 2005, WHO 2010b).
MDT, introduced in 1982, has been proved effica-
cious in Hansen’s disease treatment. Withdrawal of 
treated patients from active records, resulting in a strik-
ing decrease of prevalence, stimulated WHO to propose, 
in 1991, the elimination of Hansen’s disease by the year 
2000. The top nine most endemic countries (India, Bra-
zil, Nepal, Madagascar, Mozambique, Democratic Re-
public of Congo, Tanzania, Angola and Central African 
Republic) were not able to meet this deadline. The elimi-
nation goal was then postponed to 2005.
By the year 2008, Brazil, Nepal and East Timor had 
failed to “eliminate” leprosy as a public health problem 
(Penna et al. 2011). The National Brazilian Program 
shifted the elimination goal to decrease of leprosy in 
child in the country-plan for 2008-2011, however, after 
the governmental changes, the current policy returned 
to the elimination goal. 
Current epidemiological data from some countries 
must be carefully interpreted since the elimination tar-
gets by the year 2000 and even 2005 were obtained by 
cleaning of registers, changes in the case definition of 
Hansen’s disease, single dose treatment for PB patients 
and reduction of treatment duration to one year, among 
others (WHO 1991, Bobin 2005, Talhari & Penna 2005, 
Rodrigues & Lockwood 2011).
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